Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-24T01:12:47.597Z Has data issue: false hasContentIssue false
  • English
  • Français

Nalbuphine dependence: a brief report from the UK

Published online by Cambridge University Press:  13 June 2014

Hugh Williams ,
Andrew Remedios ,
Jan Rooney  and
Rick Hanstock
Hugh Williams
Affiliation:
Substance Misuse Service, South Downs Health NHS Trust, Brighton, BN1 4SF Department of Addictive Behaviour and Psychological Medicine, St George's Hospital Medical School, London SW17 ORE, England
Rick Hanstock
Affiliation:
Substance Misuse Service, South Downs Health NHS Trust Brighton BN1 4SF, England
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: Nalbuphine (Nubain) is a synthetic opioid analgesic with agonist-antagonist properties. This study describes a characteristic patient profile, pattern of use and treatment outcome for a series of nalbuphine dependent subjects.

Method: Retrospective systematic case-note review of uniformly collected clinical data on 11 cases of nalbuphine dependence presenting to a substance misuse service.

Results: There were nine males and two females with a mean age of 31 years of whom nine were currently employed. At presentation the mean duration of nalbuphine use was three years, the average daily dosage was 60mg (range lOmg-lOOmg) and all subjects reported injecting between two and eight times daily (mean five times daily). All subjects met opioid dependence criteria (ICD-10). Drug-related problems were multiple and varied while forensic history was uncommon. Exposure to nalbuphine occurred exclusively within the gymnasium environment and was used by bodybuilders to enhance weight training and bodybuilding. Eight subjects admitted previous anabolic steroid use, and seven current cocaine use. Eleven subjects represented 14 separate treatment episodes of which 11 treatment episodes involved the use of methadone substitution therapy. The mean stabilisation dose of methadone was 29mg (range 15mg-40mg) and in eight episodes (73%) patients were successfully retained in treatment to completion of detoxification.

Conclusions: Dependence on nalbuphine, an agonist-antagonist opioid previously believed to have low abuse potential, does occur and may be particularly associated with bodybuilders who use its analgesic properties to facilitate pain free training. Its use appears linked not only with other performance enhancing drugs (viz. anabolic steroids) but may also be associated with other psychoactive drugs such as cocaine. Methadone substitution therapy appears to be a viable treatment option.

Keywords

NalbuphineOpioid dependencePerformance enhancing drugsAnabolic steroidsBodybuilding
Type
Brief Report
Information
Irish Journal of Psychological Medicine , Volume 17 , Issue 1 , March 2000 , pp. 20 - 21
Copyright
Copyright © Cambridge University Press 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Jaffe, JH, Martin, WR. Opioid analgesics and antagonists. In: Goodman, HG, Goodman, LS et al (eds). The pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985: 511–4.Google Scholar
2.Peachy, JE. Clinical observations of agonist-antagonist analgesic dependence. Drug and Alcohol Dependence 1987; 20(4): 347–65.CrossRefGoogle Scholar
3.World Health Organisation. WHO Expert Committee on drug dependence, 25th report. WHO Technical Report Series no.775. Geneva: WHO, 1989.Google Scholar
4.Ghodse, AH. Benefit-risk of agonist-antagonist analgesics. Br J Addiction 1989;84:455–7.Google ScholarPubMed
5.Yoo, YC, Chung, HS, Kim, IS, Jin, WT, Kim, MK. Determination of nalbuphine in drug user's urine. J Analytic Toxicology 1995; 19(2): 120–3.CrossRefGoogle Scholar
6.Wines, JD, Gruber, AJ, Pope, HG, Lukas, SE. Nalbuphine hydrochloride dependence in anabolic steroid users. Am J Addictions 1999; 8: 161–4.CrossRefGoogle ScholarPubMed
7.Mc Bride, AJ, Williamson, K, Petersen, T. Three cases of nalbuphine hydrochloride dependence associated with steroid use. Br J Sports Medicine 1996; 30(1): 69–70.CrossRefGoogle ScholarPubMed